Ikena, Senti and others look to clinical presentations at AACR.

The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.

The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.

The company is stepping back in second-line breast cancer.

The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.

First-in-human study listings include EOS-215 and RO7673396.